FDA Orange Book · active-ingredient family
Ubrogepant
Ubrogepant is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.
Reference-listed drug:UBRELVY · NDA 211765
1
Brand (NDA)
0
Generics (ANDA)
16
Listed patents
0
Exclusivity periods
Brand (NDA) products · tablet
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| UBRELVYRLD×2 | ABBVIE | NDA 211765 | — | Dec 23, 2019 |
Listed patents (16)
| Patent | Expires | In | Type |
|---|---|---|---|
| 9499545 | Nov 10, 2031 | in 5 yr 6 mo | SubstanceProductU-2718 |
| 9833448 | Nov 10, 2031 | in 5 yr 6 mo | U-2718 |
| 8754096 | Jul 19, 2032 | in 6 yr 2 mo | SubstanceProductU-2717 |
| 8912210 | Dec 23, 2033 | in 7 yr 7 mo | SubstanceProduct |
| 12220408 | Jan 30, 2035 | in 8 yr 9 mo | Product |
| 12458632 | Jan 30, 2035 | in 8 yr 9 mo | Product |
| 11925709 | Jan 30, 2035 | in 8 yr 9 mo | Product |
| 12168004 | Jan 30, 2035 | in 8 yr 9 mo | Product |
| 10117836 | Jan 30, 2035 | in 8 yr 9 mo | Product |
| 12310953 | Jan 30, 2035 | in 8 yr 9 mo | Product |
| 12458633 | Jan 30, 2035 | in 8 yr 9 mo | Product |
| 11717515 | Dec 22, 2041 | in 15 yr 9 mo | U-3677 |
| 12329750 | Dec 22, 2041 | in 15 yr 9 mo | U-4213 |
| 12194030 | Dec 22, 2041 | in 15 yr 9 mo | U-4121 |
| 11857542 | Dec 22, 2041 | in 15 yr 9 mo | U-3786 |
| 12070450 | Dec 22, 2041 | in 15 yr 9 mo | U-3992 |
Ubrogepant — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
